DOCSLIB.ORG

Dr. Melanie Ott / Phd 1997 Senior Investigator, Gladstone Institute for Virology and Immunology Dr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dr. Melanie Ott / Phd 1997 Senior Investigator, Gladstone Institute for Virology and Immunology Dr Dr. Melanie Ott / PhD 1997 Senior Investigator, Gladstone Institute for Virology and Immunology Dr. Melanie Ott earned an MD from the University of Frankfurt/Main, Germany, and a PhD in Molecular Medicine from the Picower Graduate School in 1997. After receiving her PhD, Dr. Ott started her own research group at the German Cancer Research Center in Heidelberg, Germany. In 1999 and 2000, Dr. Ott was honored with the Young Researcher Award at the European Conference on Experimental AIDS Research. In 2002, Dr. Ott joined Gladstone Institute for Virology and Immunology in San Francisco as a Visiting Investigator, and later became a Staff Research Investigator and then a Senior Investigator. In 2006, she won the Hellman Award, established by F. Warren Hellman at UCSF to support the research of promising assistant professors with the capacity for great distinction in their research. She is also a recipient of the Chancellor’s Award for Public Service with UCSF for her work as founder and co-chair of the student-outreach committee at Gladstone. Dr. Ott serves as a permanent member of the AIDS Molecular Cellular Biology study section at the National Institutes of Health and is a member of scientific advisory boards of several scientific institutions, including the Pette Institute of Virology and the Helmholtz organization in Germany. Research Interests: Dr. Ott’s research focuses on two pathogens, human immunodeficiency virus (HIV-1) and hepatitis C virus (HCV), and how they interact with cells in a host. She studies the molecular mechanisms by which HIV infects and replicates in CD4 T cells, and how it wreaks havoc on part of the body’s immune system. In HCV research, Dr. Ott is examining ways by which HCV viral particles assemble within liver cells, in an attempt to understand the interactions between viral proteins, fat metabolism, and mitochondria in these infected cells. Dr. Marina Bianchi / PhD 1997 Research Fellow, Laboratory for Mother and Child Health Department of Public Health Istituto di Ricerche Farmacologiche “Mario Negri Milan, Italy Marina Bianchi obtained an MD degree from the University of Milan, Italy, and a PhD in Molecular Medicine from the Picower Graduate School in 1997. As part of her graduate work, Dr. Bianchi discovered a new compound, CNI-1493, that exerts potent anti-inflammatory activity as a result of its ability to inhibit macrophage activation. The efficacy of CNI-1493 has since then been studied in numerous animal models of inflammatory and autoimmune diseases. Dr. Bianchi returned to Italy in 2000 to take a position as Research Scientist at the Mario Negri Institute for Pharmacological Research in Milan. She is currently a member of the Laboratory for Mother and Child Health, Department of Public Health at the Mario Negri Institute where she studies pediatric chronic inflammatory and autoimmune diseases from an epidemiological perspective. Research Interests: Dr. Bianchi’s current research focuses on childhood chronic diseases, including asthma and celiac disease, and associated co-morbidities. Studies include identifying risk factors and biomarkers of childhood asthma, evaluating the appropriateness of therapy and disease management in childhood asthma, determining the correlation between appropriate ambulatory care and hospitalization for asthma in asthmatic children, and identifying the burden, causes and consequences of non-adherence to guidelines and development of strategies and interventions to enhance patient care. Dr. Ulrich Mahlknecht / PhD 1999 Head of the Department of Hematology/Oncology at St. Lukas Klinik in Solingen, Germany Dr. Ulrich Mahlknecht received his medical doctorate from the University of Tübingen in 1995 and did postgraduate medical training in internal medicine at the University of Freiburg in Freiburg in Breisgau. Dr. Mahlknecht earned a PhD in Molecular Medicine from the Picower Graduate School in 1999. After receiving his PhD, Dr. Mahlknecht completed specialist training in internal medicine and hematology/oncology at the Goethe University Frankfurt in Frankfurt am Main, where he became an Assistant Professor of Internal Medicine. From 2004 until 2007 he was an Associate Professor at the University Hospital Heidelberg where he headed the Acute Leukemias and Myelodysplastic Syndromes Task Force. In 2007 Dr. Mahlknecht became a Professor of Medicine at the Saarland University, where he currently heads the Division of Immunotherapy and Gene Therapy within the Department of Internal Medicine. Dr. Mahlknecht is president of the Clinical Epigenetics Society (CLEPSO), a non-for-profit international organization, which supports basic, translational and clinical research within the field of epigenetics. In 2009 Dr. Mahlknecht founded and became editor-in-chief of the Clinical Epigenetics journal. Since 2012 Dr. Mahlknecht has served as Head of the Department of Hematology/Oncology at the St. Lukas Klinik in Solingen, Germany. Research Interests: Clinical Epigenetics, Hematology/Oncology and Gastrontereology, Nutritional Medicine Dr. Minghuang Zhang / PhD 1999 Founder and CEO, Therapeuticure Inc. Tianjin, China Dr. Minghuang Zhang earned an MD from the Union Medical College in China, and a PhD in Molecular Medicine from the Picower Graduate School in 1999. After receiving his PhD, Dr. Zhang joined pharmaceutical companies Eisai and Nova Nordisk from 2000-2010, and founded TherapeutiCure Inc. in Tianjin, China in 2010. Dr. Zhang is currently serving in the TherapeutiCure Inc. as the President and CEO Research Interests: Inflammation and Cancer Therapeutics Dr. Giovanni Franchin / PhD 1999 Chief of Rheumatology and Associate Program Director in Medicine, Bronx-Lebanon Hospital Center and Assistant Investigator, The Feinstein Institute for Medical Research Dr. Giovanni Franchin earned an MD from Brazil Triangulo Mineiro School of Medicine, Brazil in 1993, an MSc in Immunology/Parasitology from Federal University of Sao Paulo, Sao Paulo, Brazil in 1996 and a PhD from The Picower Graduate School of Molecular Medicine in 1999. After receiving his PhD, Dr. Franchin completed a Residency in Internal Medicine at Albert Einstein College of Medicine – Montefiore Division and a Fellowship in Rheumatology at Columbia University. Dr. Franchin is board certified in Internal Medicine and Rheumatology and is a member of the American College of Rheumatology and the American Medical Association. Dr. Franchin is currently Chief of Rheumatology and Associate Program Director in Medicine, Bronx-Lebanon Hospital Center, Attending Physician at Bronx-Lebanon Hospital and Montefiore Medical Center and Assistant Investigator, The Feinstein Institute for Medical Research. Research Interests: Rheumatologic Diseases, Clinical Trials for Lupus and Rheumatoid Arthritis Dr. Günter Fingerle-Rowson / PhD 2002 Associate Group Medical Director Hoffmann LaRoche, Basel, Switzerland Dr. Günter Fingerle-Rowson earned an MD from the Ludwig-Maximilians-University, Munich, Germany, in 1993 and a PhD in Molecular Medicine from the Picower Graduate School in 2002. After receiving his PhD, Dr. Fingerle-Rowson completed training as physician in hematology/oncology and internal medicine at the Universities of Munich and Cologne, Germany. Dr. Fingerle-Rowson then worked as adjunct professor in hematology/oncology at Cologne University from 2006-2008. In addition to his clinical appointments, Dr. Fingerle-Rowson headed the laboratory of tumor biology at the Clinic I of Internal Medicine of University Hospital Cologne from 2004 – 2010, and was an active member of the German CLL Study Group (GCLLSG). In 2008, Dr. Fingerle-Rowson joined the pharmaceutical company Janssen, Neuss, Germany, as Medical Manager in the department of Medical Affairs and in 2011, F. Hoffmann-LaRoche, Basel, Switzerland, as Medical Director in Clinical Development. At present, Dr. Fingerle-Rowson works as Associate Group Medical Director in Clinical Development at Roche and leads the development of Obinutuzumab (Gazyva) in B cell malignancies. During his leadership, worldwide approvals for Obinutuzumab in frontline treatment of chronic lymphocytic leukemia (CLL-11 Ph3 trial) and rituximab-refractory indolent Non-Hodgkin lymphoma (NHL) (Gadolin Ph3 trial) were achieved and Obinutuzumab is being developed in innovative combinations for the treatment of B cell malignancies and immunological diseases. Research Interests: Tumor immunology and biology, Clinical development of novel drugs in the field of B cell malignancies Dr. Maowen Hu / PhD 2002 Radiologist, UCSF Medical Center, Kaiser Hospital, North Valley, CA Dr. Maowen Hu earned an MD from Shandong University, China in 1991, an MSc in Pharmacology from Shandong University in 1994, an MSc in Biomedical Sciences from the University of Rhode Island in 1999, and a PhD in Molecular Medicine from the Picower Graduate School in 2002. From 2002-2007, Dr. Hu was a Research Fellow/Scientist in the Department of Surgery, North Shore-LIJ Health System, New York. After receiving her PhD, Dr. Hu joined Feinstein Research Institute for Medical research, focusing on acute lung injury. Then she completed the radiology residency at Mount Sinai Medical Center Miami, and the women’s imaging fellowship at University of California San Francisco. Dr. Hu is currently a diagnostic radiologist working in the North Valley Kaiser Permanente Medical Group California. She specializes in mammography and breast procedures. Research Interests: Radiology, Breast Imaging, Ultrasound Dr. Jianlin Xie / PhD 2002 Assistant (Clinical) Professor,
Load more

Recommended publications
  • Unexpected Side Effects of Everyday Medication Through Sirtuin1 Modulation
    223-232 9/1/08 16:06 Page 223 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 21: 223-232, 2008 223 Aging and anti-aging: Unexpected side effects of everyday medication through sirtuin1 modulation NICOLE ENGEL2 and ULRICH MAHLKNECHT1,2 1Saarland University Medical Center, Department of Hematology/Oncology, José Carreras Center for Immunotherapy and Gene Therapy, D-66424 Homburg/Saar; 2Department of Hematology/Oncology, University of Heidelberg Medical Center, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany Received August 28, 2007; Accepted October 19, 2007 Abstract. The sirtuin 1 protein (SIRT1) is a member of the Introduction class III NAD+-dependent histone deacetylases, which are also referred to as the ‘sirtuins’. The sirtuins and silent Reversible DNA and protein modification, such as acetylation information regulator 1 (SIRT1) in particular, are known to and deacetylation, are involved in the regulation of tran- play a role in the response to DNA damage, metabolism, scriptional activity and influence protein enzymatic activity. longevity and carcinogenesis. SIRT1 regulates different Acetylation of histone N-terminal lysine residues is carried cellular processes such as proliferation, differentiation and out by histone acetyltransferases (HATs) and is associated apoptosis through deacetylation of important regulatory with increased transcriptional activity in eukaryotic cells proteins such as p53, FOXO3a and NFκB. A number of through chromatin relaxation and may be reversed by different modifiers of SIRT1 expression and activity have competing histone deacetylase (HDAC) enzymatic activities, been discovered and even food and cosmetic additives (e.g. which cause histone deacetylation and thus chromatin resveratrol and dihydrocoumarin) have been suggested to condensation and subsequently repression of gene expression either activate or inhibit the activity of human SIRT1.
    [Show full text]
  • 5183 Mol Med Review Pp623-644
    Molecular Medicine 6(8): 623–644, 2000 Molecular Medicine © 2000 The Picower Institute Press Review Article Histone Acetylation Modifiers in the Pathogenesis of Malignant Disease Ulrich Mahlknecht and Dieter Hoelzer Department of Hematology/Oncology, University of Frankfurt Medical Center, Frankfurt, Germany Abstract Chromatin structure is gaining increasing attention human acute leukemias and solid tumors, where fu- as a potential target in the treatment of cancer. sions of regulatory and coding regions of a variety Relaxation of the chromatin fiber facilitates tran- of transcription factor genes result in completely scription and is regulated by two competing enzy- new gene products that may interfere with matic activities, histone acetyltransferases (HATs) regulatory cascades controlling cell growth and and histone deacetylases (HDACs), which modify differentiation. On the other hand, some histone the acetylation state of histone proteins and acetylation–modifying enzymes have been located other promoter-bound transcription factors. While within chromosomal regions that are particularly HATs, which are frequently part of multisubunit prone to chromosomal breaks. In these cases gains coactivator complexes, lead to the relaxation of and losses of chromosomal material may affect the chromatin structure and transcriptional activation, availability of functionally active HATs and HDACs, HDACs tend to associate with multisubunit core- which in turn disturbs the tightly controlled equi- pressor complexes, which result in chromatin librium of histone acetylation. We review herein the condensation and transcriptional repression of spe- recent achievements, which further help to eluci- cific target genes. HATs and HDACs are known to date the biological role of histone acetylation modi- be involved both in the pathogenesis as well as in fying enzymes and their potential impact on our the suppression of cancer.
    [Show full text]
  • SNP Analyses in Cytarabine Metabolizing Enzymes In
    Letters to the Editor 1929 Research Council, The Danish Cancer Society, The John and logic malignancies and inherited blood disorders. Mol Ther 2006; Birthe Meyer Foundation, and the Toyota Foundation. 13: 26–41. 2 Kolb HJ. Graft-versus-leukemia effects of transplantation and donor L Wenandy1, T Kollgaard1, A Letsch2, lymphocytes. Blood 2008; 112: 4371–4383. RS Andersen1, D Stather2 , T Seremet1, IM Svane1,3, 3 Wang W, Meadows LR, den Haan JM, Sherman NE, Chen Y, L Vindeløv4, MH Andersen1 and P thor Straten1 Blokland E et al. Human H-Y: a male-specific histocompatibility 1Department of Hematology, Center for Cancer Immune antigen derived from the SMCY protein. Science 1995; 269: Therapy (CCIT), Herlev University Hospital, Herlev, Denmark; 1588–1590. 2Department of Hematology, Oncology, Charite´, 4 Spierings E, Wieles B, Goulmy E. Minor histocompatibility Berlin, Germany; antigens–big in tumour therapy. Trends Immunol 2004; 25: 56–60. 3 5 Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes Department of Oncology, Herlev University Hospital, H et al. Identification of new HER2/neu-derived peptide epitopes Herlev, Denmark and 4 that can elicit specific CTL against autologous and allogeneic The Hematopoietic Cell Transplantation Laboratory, carcinomas and melanomas. J Immunol 1999; 163: 1037–1044. Department of Hematology, Rigshospitalet, 6 Muller MR, Grunebach F, Kayser K, Vogel W, Nencioni A, Brugger Copenhagen, Denmark W et al. Expression of her-2/neu on acute lymphoblastic leukemias: E-mail: [email protected] implications for the development of immunotherapeutic approaches. Clin Cancer Res 2003; 9: 3448–3453. 7 Schuler MM, Donnes P, Nastke MD, Kohlbacher O, Rammensee HG, Stevanovic S.
    [Show full text]
  • Azacytidine Causes Complex DNA Methylation Responses in Myeloid Leukemia
    2998 Azacytidine causes complex DNA methylation responses in myeloid leukemia Carlo Stresemann,1 Imke Bokelmann,2 Introduction 2 1 Ulrich Mahlknecht, and Frank Lyko The azanucleosides 5-azacytidine (azacytidine) and 2¶-deoxy-5-azacytidine (decitabine) are two closely related 1Division of Epigenetics, German Cancer Research Center; 2Department of Hematology/Oncology, University of Heidelberg compounds that have found increasing clinical use for the Medical Center, Heidelberg, Germany treatment of myeloid leukemias (1,2). Azanucleosides are cytosine analogues that can become incorporated into nucleic acids and thereby exert a wide range of molecular Abstract effects. Although the precise mode of action of these drugs Aberrant DNA methylation patterns play an important role remains to be established,both azacytidine and decitabine in the pathogenesis of hematologic malignancies. The have been found to be particularly effective in inducing DNA methyltransferase inhibitors azacytidine and decita- DNA demethylation and epigenetic gene reactivation bine have shown significant clinical benefits in the in vitro (3,4). These effects are caused by covalent trapping treatment of myelodysplastic syndrome (MDS), but their of DNA methyltransferases through DNA-incorporated precise mode of action remains to be established. Both azacytosine bases and subsequent degradation of the drugs have been shown the ability to deplete DNA trapped enzymes (5,6). methyltransferase enzymes and to induce DNA demethy- Azacytidine and decitabine have shown significant lation and epigenetic reprogramming in vitro. However, clinical benefits in the treatment of myelodysplastic drug-induced methylation changes have remained poorly syndrome (MDS; refs. 7,8) and have subsequently obtained characterized in patients and therapy-related models. We Food and Drug Administration approval for this indica- have now analyzed azacytidine-induced demethylation tion.
    [Show full text]
  • Myelodysplastische Syndrome (MDS) Leitlinie
    Myelodysplastische Syndrome (MDS) Leitlinie Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen Herausgeber DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. Alexanderplatz 1 10178 Berlin Geschäftsführender Vorsitzender: Prof. Dr. med. Mathias Freund Telefon: +49 (0)30 27 87 60 89 - 0 Telefax: +49 (0)30 27 87 60 89 - 18 [email protected] www.dgho.de Ansprechpartner Prof. Dr. med. Bernhard Wörmann Medizinischer Leiter Quelle www.dgho-onkopedia.de Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr. Inhaltsverzeichnis 1 Definition und Basisinformationen .................................................. 2 2 Klinisches Bild ............................................................................... 2 3 Diagnostik und Differentialdiagnosen ............................................. 3 4 Prognose....................................................................................... 7 5 Therapie der Niedrigrisiko-MDS (IPSS LOW und IPSS INT-1) .............. 9 5.1 Therapieindikation ......................................................................................... 9 5.2 Supportive Therapie..................................................................................... 10 5.3
    [Show full text]
  • MDS Foundation Fall 2013
    fall/winter 2013: volume 19, issue 2 newsletter of the myelodysplastic syndromes foundation MDS NEWS HIGHLIGHTS FROM THE GUEST EDITOR’S DESK I 12th International Symposium on MDS: An Overview Presented by Prof. Dr. med. Wolf-Karsten Hofmann and Prof. Dr. med. Arnold Ganser FEATURING MDS CLINICAL TOOLBOX ASH 2013 MDS FOUNDATION BREAKFAST SYMPOSIUM December 6, 2013 • New Orleans, Louisiana I PLAN TO ATTEND! TABLE OF CONTENTS TABLE OF CONTENTS FROM THE GUEST EDITOR’S DESK 2 MDS Resources: Literature Highlights 18 12th International MDS Symposium 4 Patient Initiatives Revised International Prognostic Scoring System for MDS 5 Patient and Caregivers LIVING with MDS Forums 20 The MDS Forum – Berlin, Germany 6 MDS Patient Support Groups 21 About The Foundation 9 Patient and Family Contributions 23 Meeting Highlights/Announcements ASH 2013 MDS FOUNDATION Fundraising for MDS Foundation 29 BREAKFAST SYMPOSIUM 10 Nursing in MDS 30 International MDS Symposia 11 Information on Clinical Trials 31 From The Foundation MDS Centers of Excellence 32 Building Blocks of Hope 13 Contributions to the Foundation MDS CLINICAL TOOLBOX 14 Thank You 38 MDS Awareness 15 Memorial Donations 39 In Memory of Robert Weinberg 16 MDS Foundation Information 40 www.mds-foundation.org FROM THE GUEST EDITOR’S DESK INTERNATIONAL SYMPOSIUM ON MYELODYSPLASTIC SYNDROMES 12th International Symposium on MDS: An Overview As a novelty to this meeting, the plenary sessions not only consisted of classical well as discussions on challenging cases plenary talks but also one oral presentation from the daily practice of the attending on original data submitted to the congress doctors. The infectious enthusiasm of the thereby providing a prominent platform to faculty, namely Teresa Vallespi (Spain), young investigators and researchers.
    [Show full text]
  • Dr. Melanie Ott / Phd 1997 Senior Investigator, Gladstone Institute for Virology and Immunology Dr
    Dr. Melanie Ott / PhD 1997 Senior Investigator, Gladstone Institute for Virology and Immunology Dr. Melanie Ott earned an MD from the University of Frankfurt/Main, Germany, and a PhD in Molecular Medicine from the Picower Graduate School in 1997. After receiving her PhD, Dr. Ott started her own research group at the German Cancer Research Center in Heidelberg, Germany. In 1999 and 2000, Dr. Ott was honored with the Young Researcher Award at the European Conference on Experimental AIDS Research. In 2002, Dr. Ott joined Gladstone Institute for Virology and Immunology in San Francisco as a Visiting Investigator, and later became a Staff Research Investigator and then a Senior Investigator. In 2006, she won the Hellman Award, established by F. Warren Hellman at UCSF to support the research of promising assistant professors with the capacity for great distinction in their research. She is also a recipient of the Chancellor’s Award for Public Service with UCSF for her work as founder and co-chair of the student-outreach committee at Gladstone. Dr. Ott serves as a permanent member of the AIDS Molecular Cellular Biology study section at the National Institutes of Health and is a member of scientific advisory boards of several scientific institutions, including the Pette Institute of Virology and the Helmholtz organization in Germany. Research Interests: Dr. Ott’s research focuses on two pathogens, human immunodeficiency virus (HIV-1) and hepatitis C virus (HCV), and how they interact with cells in a host. She studies the molecular mechanisms by which HIV infects and replicates in CD4 T cells, and how it wreaks havoc on part of the body’s immune system.
    [Show full text]